Admedus has announced that it now has a medical device licence to market CardioCel in Canada, which means that Canada becomes the latest market in the global launch of the product following sales in Europe and the USA. A press release states that CardioCel is the company’s lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves.
The launch of CardioCel in Canada is part of a continuing global strategy to gain product regulatory approval in major markets and directly secure key centres and surgeons as customers. The marketing of CardioCel in Canada will be undertaken by the Admedus North American sales team.
“The Canadian approval is another important step in the global launch of CardioCel and will add revenue growth for the Admedus Group,” says Lee Rodne, chief executive officer of Admedus.